Johnson & Johnson agreed to buy Ollin Biosciences in a deal worth up to $3.3 billion, reinforcing pharma’s ophthalmology buildout. The acquisition comes a little over a year after Ollin revealed its approach, and it adds to J&J’s expansion in eye disease therapeutics. The transaction signals continued appetite for late-stage or platform-adjacent ophthalmic innovation, with deal size reflecting expectations that the target pipeline can be scaled within J&J’s clinical and commercialization infrastructure. For investors and biotech operators, the move also highlights how ophthalmology remains a favored sector for large-company acquisitions, particularly when platforms can be integrated into broader commercial strategies.
Get the Daily Brief